<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176653</url>
  </required_header>
  <id_info>
    <org_study_id>SLN124-001</org_study_id>
    <nct_id>NCT04176653</nct_id>
  </id_info>
  <brief_title>Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124</brief_title>
  <official_title>Phase 1b Single Ascending and Multiple Dose First-in-man Study in Adult Patients With Non-transfusion-dependent Beta-thalassaemia or Low Risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN124</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silence Therapeutics plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Silence Therapeutics plc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the safety and tolerability of SLN124 for
      the treatment of non-transfusion-dependent (NTD) β-thalassaemia and low risk myelodysplastic
      syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study stopped prior to subject administered first dose, due to COVID-19
  </why_stopped>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">October 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multiple Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure># of participants with all AEs as assessed by CTCAE V4.0 included injection site reaction, will be measured from baseline to post dose follow up</measure>
    <time_frame>Up to two months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 lead electrocardiogram parameters included PR, QTcF and QTcB will be measured from baseline to post dose follow up</measure>
    <time_frame>Up to two months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical chemistry, haematology, urinalysis, liver function tests (included ALT, AST, GGT) will be measured from baseline to post dose follow up</measure>
    <time_frame>Up to two months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>height, weight, blood pressure, heart rate, respiration rate and temperature will be measured from baseline to post dose follow up</measure>
    <time_frame>Up to two months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers will be measured from baseline to post dose follow up</measure>
    <time_frame>Up to two months</time_frame>
    <description>serum hepcidin level (ng/ml), ferritin level (ug/L), Transferrin saturation (%), iron level (umol/L), haemoglobin and reticulocyte count will be analysed by central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of SLN124 in plasma from baseline to post dose follow up</measure>
    <time_frame>Up to two months</time_frame>
    <description>Peak Plasma Concentration (Cmax) will be analysed by central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic of SLN124 in plasma from baseline to post dose follow up</measure>
    <time_frame>Up to two months</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) will be analysed by central laboratory.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-transfusion-dependent Thalassemia</condition>
  <condition>Low Risk Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo</intervention_name>
    <description>IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.</description>
    <arm_group_label>0.3 mg/kg</arm_group_label>
    <arm_group_label>1.0 mg/kg</arm_group_label>
    <arm_group_label>10.0 mg/kg</arm_group_label>
    <arm_group_label>3.0 mg/kg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18yrs; BMI 18-35 kg/m2

          -  β-thalassaemia intermedia or compound heterozygous HbE/β-thalassaemia

          -  Non-transfusion dependent: ≤ 5 units red cells in last 6 months and transfusion-free
             for ≥8 weeks

          -  Hb between 5 &amp; 11 g/dL

          -  Ferritin &gt; 250 µg/L and /or liver iron ≥ 3mg Fe/g dry weight and TSAT &gt;40%

        Exclusion Criteria:

          -  Haemoglobin S/β-thalassaemia, homozygous β-0 thalassaemia or α thalassaemia

          -  ALT/AST &gt; 1.5 x upper limit normal or cirrhosis

          -  eGFR &lt; 60 mL/min/1.73m2

          -  Platelets &lt;100 or &gt; 1000 x 109/L

          -  Untreated B12/folate deficiency

          -  Iron chelation therapy unless stable for ≥8 weeks

          -  Daily NSAID, therapeutic dose anticoagulant, ESA ≤12 weeks or stable dosing of
             hydroxyurea ≤ 6 months

          -  Significant cardiac disease (MI in 6 months, NYHA class III-IV heart failure, long QT)

          -  HIV or active hepatitis B/C or malignancy within 5 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MHAT Dr. Nikola Vasiliev AD</name>
      <address>
        <city>Kyustendil</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Dr. Georgi Stranski AD</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center COMAC MEDICAL</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Sv. Ivan Rilski</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

